{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:51Z","timestamp":1793047071796,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.schres.2026.06.013","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:07:30Z","timestamp":1781496450000},"page":"212-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy of oral and long-acting injectable paliperidone on social functioning in schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"295","author":[{"given":"Yue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-859X-10-12","article-title":"Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial","volume":"10","author":"Alphs","year":"2011","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/NDT.S36438","article-title":"Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics","volume":"9","author":"Alphs","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.20982\/tqmp.12.3.p154","article-title":"Fitting three-level meta-analytic models in R: a step-by-step tutorial","volume":"12","author":"Assink","year":"2016","journal-title":"Quant. Methods Psychol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0025","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/eip.12685","article-title":"Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia","volume":"13","author":"Bell Lynum","year":"2019","journal-title":"Early Interv. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0030","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2020.72","article-title":"Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: a retrospective 6-month mirror-image study","volume":"63","author":"Bioque","year":"2020","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2026.06.013_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40261-018-0734-1","article-title":"Effects on satisfaction and service engagement of paliperidone palmitate compared with oral paliperidone in patients with schizophrenia: an open label randomized controlled trial","volume":"39","author":"Bozzatello","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.schres.2026.06.013_bb0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1744-859X-10-18","article-title":"The importance of measuring psychosocial functioning in schizophrenia","volume":"10","author":"Brissos","year":"2011","journal-title":"Ann. General Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/YIC.0b013e3282fce651","article-title":"Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone","volume":"23","author":"Canuso","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1751-7893.2010.00165.x","article-title":"Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia","volume":"4","author":"Canuso","year":"2010","journal-title":"Early Interv. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2026.06.013_bb0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jad.2009.05.025","article-title":"Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms","volume":"120","author":"Canuso","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.schres.2026.06.013_bb0060","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/NDT.S47276","article-title":"An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients","volume":"9","author":"Charnsil","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0065","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11126-017-9494-y","article-title":"Reliability and validity of the short version of Udvalg for Kliniske Undersogelser in antipsychotic treatment","volume":"88","author":"Chen","year":"2017","journal-title":"Psychiatry Q."},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.9758\/cpn.2022.20.3.427","article-title":"Asian subgroup analysis of the REMISSIO study: a long-term efficacy and safety study of paliperidone palmitate 3-month formulation in patients with stable schizophrenia in a naturalistic clinical setting","volume":"20","author":"Chung","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"10","key":"10.1016\/j.schres.2026.06.013_bb0075","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14737175.2017.1371014","article-title":"Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications","volume":"17","author":"Citrome","year":"2017","journal-title":"Expert. Rev. Neurother."},{"issue":"2","key":"10.1016\/j.schres.2026.06.013_bb0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0034-7450(14)60009-3","article-title":"Study of flexible doses of Paliperidone ER in pacients with schizophrenia who have undergone inefficient treatment with other antipsychotics","volume":"41","author":"C\u00f3rdoba","year":"2012","journal-title":"Rev. Colomb. Psiquiatr."},{"issue":"7","key":"10.1016\/j.schres.2026.06.013_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21495","article-title":"Three-year outcomes of 6-month paliperidone palmitate in adults with schizophrenia: an open-label extension study of a randomized clinical trial","volume":"7","author":"Correll","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1017\/S1092852924000476","article-title":"Comparing two transitioning strategies to paliperidone palmitate once-every-6-months","volume":"29","author":"Correll","year":"2024","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12888-025-07155-x","article-title":"Efficacy of paliperidone palmitate once-monthly (PP1M) in improving social functioning and reducing caregiver burden in patients with schizophrenia: a six-month follow-up study","volume":"25","author":"Dong","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0100","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2147\/NDT.S142634","article-title":"Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia","volume":"13","author":"Emsley","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.06.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320926347","article-title":"Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia","volume":"10","author":"Garcia-Portilla","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2026.06.013_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14656566.2021.2023496","article-title":"Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study","volume":"23","author":"Garcia-Portilla","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1185\/03007995.2013.869201","article-title":"Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study","volume":"30","author":"Gattaz","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.schres.2026.06.013_bb0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"sup3","key":"10.1016\/j.schres.2026.06.013_bb0125","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1080\/15622975.2017.1315176","article-title":"Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia","volume":"19","author":"Hargarter","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/2045125315584870","article-title":"Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia","volume":"5","author":"Helldin","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.schres.2026.06.013_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6904-12-1","article-title":"Effects of paliperidone extended release on the symptoms and functioning of schizophrenia","volume":"12","author":"Huang","year":"2012","journal-title":"BMC Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/pcn.13304","article-title":"Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study","volume":"76","author":"Ishigooka","year":"2022","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12888-024-06031-4","article-title":"Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning","volume":"24","author":"Ishigooka","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40263-018-0508-6","article-title":"Long-acting injectable second-generation antipsychotics: an update and comparison between agents","volume":"32","author":"Jann","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2026.06.013_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/NDT.S112063","article-title":"Effects of paliperidone extended release on hostility among Thai patients with schizophrenia","volume":"13","author":"Jariyavilas","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.schres.2026.06.013_bb0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pnpbp.2012.04.004","article-title":"The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia","volume":"38","author":"Kim","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2026.06.013_bb0175","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2013.816277","article-title":"Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents","volume":"29","author":"Kim","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0180","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13446","article-title":"Effects of long-acting injectable paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration","volume":"82","author":"Kim","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/YIC.0000000000000093","article-title":"Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics","volume":"30","author":"Kwon","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2026.06.013_bb0195","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0200","first-page":"15","article-title":"Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study","volume":"12","author":"Li","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.06.013_bb0205","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2147\/NDT.S157399","article-title":"Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study","volume":"14","author":"Li","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12888-024-05508-6","article-title":"Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review","volume":"24","author":"Li","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-859X-12-22","article-title":"Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies","volume":"12","author":"Markowitz","year":"2013","journal-title":"Ann. General Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/YIC.0000000000000092","article-title":"Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach","volume":"30","author":"Mauri","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2026.06.013_bb0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"5","key":"10.1016\/j.schres.2026.06.013_bb0230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0235","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/13645579.2016.1252189","article-title":"Methods for dealing with multiple outcomes in meta-analysis: a comparison between averaging effect sizes, robust variance estimation and multilevel meta-analysis","volume":"20","author":"Moeyaert","year":"2017","journal-title":"Int. J. Soc. Res. Methodol."},{"issue":"8","key":"10.1016\/j.schres.2026.06.013_bb0240","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ijnp\/pyad028","article-title":"Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia","volume":"26","author":"Najarian","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.06.013_bb0245","first-page":"1511","article-title":"The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia","volume":"11","author":"Nakagawa","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"10","key":"10.1016\/j.schres.2026.06.013_bb0250","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2026.06.013_bb0255","author":"NHLBI"},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0260","doi-asserted-by":"crossref","first-page":"126","DOI":"10.9758\/cpn.2023.21.1.126","article-title":"Effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social performance of patients with schizophrenia","volume":"21","author":"Oh","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.schres.2026.06.013_bb0265","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.schres.2026.06.013_bb0270","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clinthera.2010.02.003","article-title":"Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets","volume":"32","author":"Patrick","year":"2010","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11121-021-01246-3","article-title":"Meta-analysis with robust variance estimation: expanding the range of working models","volume":"23","author":"Pustejovsky","year":"2022","journal-title":"Prev. Sci."},{"issue":"34","key":"10.1016\/j.schres.2026.06.013_bb0280","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034623","article-title":"Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: an Asian subgroup analysis of phase 3, randomized study","volume":"102","author":"Richarz","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.schres.2026.06.013_bb0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaac.2014.11.009","article-title":"Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study","volume":"54","author":"Savitz","year":"2015","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2026.06.013_bb0290","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/YIC.0000000000000190","article-title":"Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study","volume":"32","author":"Savitz","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2026.06.013_bb0300","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/NDT.S134287","article-title":"Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study","volume":"13","author":"Savitz","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"8","key":"10.1016\/j.schres.2026.06.013_bb0305","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1185\/03007995.2012.708327","article-title":"Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study","volume":"28","author":"Schmauss","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.schres.2026.06.013_bb0310","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.clinthera.2014.08.014","article-title":"A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents","volume":"36","author":"Schreiner","year":"2014","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.schres.2026.06.013_bb0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-016-4445-0","article-title":"Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study","volume":"234","author":"Schreiner","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2026.06.013_bb0320","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2147\/NDT.S112542","article-title":"Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study","volume":"12","author":"Shi","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.06.013_bb0325","first-page":"1483","article-title":"Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study","volume":"11","author":"Si","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013688","article-title":"Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: post hoc analysis of an open-label, prospective study","volume":"98","author":"Si","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.schres.2026.06.013_bb0335","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2147\/NDT.S191803","article-title":"Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia","volume":"15","author":"Si","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2026.06.013_bb0340","article-title":"Assessment of the minimum clinically important difference in symptoms and functions of patients with acute schizophrenia: a post hoc analysis of an open-label, single-arm multicenter study","volume":"12","author":"Si","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2026.06.013_bb0345","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0350","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2026.06.013_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110619","article-title":"Switching from risperidone to paliperidone palmitate in schizophrenia: changes in social functioning and cognitive performance","volume":"120","author":"Tost","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.06.013_bb0360","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3109\/08039488.2014.996252","article-title":"Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: an open-label, single-arm, flexible-dose, 12-months follow-up study","volume":"69","author":"\u00dc\u00e7ok","year":"2015","journal-title":"Nord. J. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2026.06.013_bb0365","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.schres.2026.06.013_bb0370","series-title":"Persistence With and Adherence to Paliperidone Palmitate Once-monthly Injection for Schizophrenia Treatment in China and Japan","author":"Wang","year":"2021"},{"key":"10.1016\/j.schres.2026.06.013_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2023.110897","article-title":"A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior","volume":"129","author":"Wang","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis","volume":"83","author":"Wang","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.06.013_bb0385","author":"WHO"},{"issue":"3","key":"10.1016\/j.schres.2026.06.013_bb0390","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","article-title":"Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)","volume":"10","author":"Winter-van Rossum","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2026.06.013_bb0395","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/NDT.S130483","article-title":"Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication","volume":"13","author":"Yang","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"11","key":"10.1016\/j.schres.2026.06.013_bb0400","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s12325-017-0638-0","article-title":"Paliperidone palmitate improves and maintains functioning in Asia-Pacific patients with schizophrenia","volume":"34","author":"Zhang","year":"2017","journal-title":"Adv. Ther."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426001969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:06:20Z","timestamp":1793045180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426001969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":79,"alternative-id":["S0920996426001969"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.013","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of oral and long-acting injectable paliperidone on social functioning in schizophrenia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}